Supplements vergleichen

Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the MORE, CORE, RUTH and STAR trials all used 60 mg/day; MORE also tested 120 mg/day with no clear added fracture benefit and more side effects). For off-label male gynecomastia the small published pediatric series used roughly 60 mg/day; there is no FDA-approved male dose and the male evidence is thin and retrospective.

Any time

Raloxifenhydrochlorid 60-mg-Tabletten (zugelassen für postmenopausale Osteoporose und Senkung des Brustkrebsrisikos)

20mg

Evening · with food (preferred)

Zinkpicolinat oder Zinkcitrat

• Active or past history of venous thromboembolism (deep-vein thrombosis, pulmonary embolism, retinal-vein thrombosis) — raloxifene raises clot risk
• Pregnancy and breastfeeding (can harm the fetus; contraindicated)
• Women of childbearing potential / premenopausal women (not indicated)

• Warfarin / anticoagulants
• Cholestyramine
• Systemic estrogens / other SERMs / aromatase inhibitors

• Copper deficiency (zinc depletes copper)

• Antibiotics (fluoroquinolones, tetracyclines)
• Penicillamine
• Diuretics